Department of Bio-Analytical Chemistry, Niigata University of Pharmacy and Applied Life Sciences.
Department of Health Chemistry, Niigata University of Pharmacy and Applied Sciences.
Biol Pharm Bull. 2021;44(4):485-493. doi: 10.1248/bpb.b20-00663.
Many pharmaceuticals and dietary foods have been reported to inhibit cholesterol biosynthesis, mainly by inhibiting the presqualene enzyme 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase rather than a postsqualene enzyme. In this study, we examined the inhibitory effects of Latilactobacillus sakei UONUMA on cholesterol biosynthesis, especially postsqualene, in human HepG2 hepatoma cells. We quantified cholesterol and its precursors, and the mRNA and protein levels of enzymes involved in cholesterol biosynthesis. Three L. sakei UONUMA strains exhibited new inhibitory effects on cholesterol biosynthesis and inhibited the mRNA level of sterol-delta24-reductase (DHCR24), which is involved in the postsqualene cholesterol biosynthesis pathway. These strains will be useful for the prevention and treatment of hyperlipidemia.
许多药物和膳食食品已被报道能抑制胆固醇生物合成，主要是通过抑制前鲨烯酶 3-羟基-3-甲基戊二酰辅酶 A（HMG-CoA）还原酶，而不是鲨烯后酶。在这项研究中，我们研究了清酒乳杆菌 UONUMA 对胆固醇生物合成，特别是鲨烯后阶段，在人肝癌 HepG2 细胞中的抑制作用。我们定量了胆固醇及其前体，以及胆固醇生物合成相关酶的 mRNA 和蛋白水平。三种清酒乳杆菌 UONUMA 株对胆固醇生物合成表现出了新的抑制作用，并抑制了鲨烯后胆固醇生物合成途径中的甾醇-Δ24-还原酶（DHCR24）的 mRNA 水平。这些菌株将有助于预防和治疗高血脂症。
